Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Gerson Hernandez

Gerson Hernandez

Assistant Research Professor, Neurology | Senior Director, Clinical Trials - Center for Innovation in Brain Science

Collaboration(11)

Roberta Brinton
Floyd Chilton
David Labiner
Kathleen Rodgers
Fei Yin

Page 1 of 3

Grants(5)

Expanding AD Biomarkers in NIA funded PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Tria
Active·2024·$4.4M / $1.8M·
External
Co-Investigator (COI)
biomarkers, menopause, brain metabolism, cognition, clinical trial
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
Active·2022·$2.5M / $5M·
External
Multiple Principal Investigator (MPI)
phytoserm, menopause, brain metabolism, cognition, clinical trial
PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health
Active·2020·$173.9K / $347.9K·
External
Co-Investigator (COI)
phytoserm, menopausal, hot flashes, brain health, sustained
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial
Active·2019·$1.5M / $30.6M·
External
Co-Investigator (COI)
alzheimer's, regenerative therapy, clinical trial, allopregnanolone, neurodegeneration
Precision Functional Assessment for Alzheimer's Disease: It's Personal
2018·$2K / $100K·
External
Co-Investigator (COI)
alzheimer's disease, functional assessment, precision medicine, personalized healthcare, neurological disorders

Publications(6)

Recent

In‐season docosahexaenoic acid supplementation does not prevent white matter damage during a single American football season: Implications for neurodegeneration prevention

2022

neurodegeneration, supplementation, white matter damage, in‐season, american football

Allopregnanolone as a Regenerative Therapeutic for Alzheimer rsquo;s Disease: Phase 2 proof‐of‐concept clinical trial using hippocampal volume as a surrogate endpoint

2022

alzheimer's disease, regenerative therapeutic, allopregnanolone, hippocampal volume

Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer s disease: Structural effects and functional connectivity outcomes

2022

alzheimer's disease, allopregnanolone, imaging outcomes, regenerative therapeutic, clinical trial

Pharmacokinetics and safety profile of intramuscular administration of allopregnanolone in patients with Alzheimer rsquo;s disease: Human/Human trials: Other

2020

pharmacokinetics, safety, alzheimer's disease, intramuscular administration, clinical trials

Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer s disease: A single and multiple ascending dose phase 1b/2a clinical trial

2020

alzheimer's disease, pharmacokinetics, safety, regenerative therapeutic, clinical trial

P3-032: COMBINING SEX, APOE GENOTYPE, AND MITOCHONDRIAL GENETIC VARIANCE AS PREDICTIVE RESPONDER IDENTIFIER TO REGENERATIVE THERAPEUTIC ALLOPREGNANOLONE FOR ALZHEIMER S DISEASE

2019

alzheimer's disease, genetic variance, regenerative therapeutic, mitochondrial genetics, personalized medicine